CANNAINVESTOR Magazine U.S. Publicly Traded April / May 2019 | Page 160

196

You may recall from my hypothesis last summer and subsequent follow up content that I suggested genomics (pharmacogenetics / personalized medicine) may be a key because we can take two as identical as possible individuals with the same medical condition and they may have different responses from the same cannabis. When developing my hypothesis, I reached out to Aleafia Health Inc (TSXV:AEF) for some information and feedback on my hypothesis. Before long, Aleafia announced they were starting research into genomics with respect to cannabis pharmacogenetics. What should now be no surprise to you is that genomics is also deemed key in phage derived therapy.

Whether our health and wellness hypothesis or about investing and our other content … there is a reason why I believe that CannaInvestor Magazine leads the way and that will always be your advantage.

Once again, this article does not really discuss investments yet it is completely about investing in the cannabis and hemp industry because of the resulting global paradigm shift that could be coming. Investing is not just about buying securities. It is about careers. It is about entrepreneurship and pioneering. It is about medical and scientific breakthroughs. It is about societal awareness that leads to education and learning. It is about a paradigm shift that in turn will influence governmental policy. It is about the rights of the individual.

160